rare_disease_therapeutics

Lancet Publishes Capricor HOPE-3 Data Ahead of Aug. 22 FDA Date

Image
Lancet Publishes Capricor HOPE-3 Data Ahead of Aug. 22 FDA Date

San Diego – October 19, 2026 -- Capricor Therapeutics (NASDAQ: CAPR) said The Lancet has published results from its Phase 3 HOPE-3 trial, in which Deramiocel slowed upper limb function decline by 54 percent versus placebo in Duchenne muscular dystrophy (PUL 2.0, p=0.03).

The randomized, double-blind, placebo-controlled trial enrolled 106 participants and met its primary endpoint. Capricor also reports a clinically meaningful cardiac benefit. The results rest on the company's prespecified Statistical Analysis Plan version 3.0 (SAP 3.0).

Brogidirsen Shows 5-Year Motor Function Benefit in DMD Trial

Image
Brogidirsen Shows 5-Year Motor Function Benefit in DMD Trial

Paramus, N.J. – October 01, 2026 -- NS Pharma, Inc. reported 5-year efficacy and safety data showing its investigational therapy brogidirsen maintained or improved motor function in Duchenne muscular dystrophy (DMD) patients amenable to exon 44 skipping, with zero treatment discontinuations across the study period.

Six-participant trial records no serious adverse events over five years

The data, presented by Japan's National Center of Neurology and Psychiatry (NCNP) at the 31st annual International Congress of the World Muscle Society in Hiroshima, Japan, covered an open-label extension of an investigator-initiated clinical trial. All six participants received weekly intravenous dosing of brogidirsen (NS-089/NCNP-02), an antisense oligonucleotide co-discovered by Nippon Shinyaku and NCNP. After five years of administration, no serious or severe adverse events, anaphylaxis, or discontinuations tied to long-term dosing were recorded.

Protalix CFO to Present at H.C. Wainwright, Morgan Stanley Healthcare Conferences

Image
Protalix CFO to Present at H.C. Wainwright, Morgan Stanley Healthcare Conferences

Carmiel, Israel – September 13, 2026 -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) confirmed that Chief Financial Officer Gilad Mamlok will represent the company at two investor conferences in New York City this month.

Mamlok addresses H.C. Wainwright's 28th Annual Global Investment Conference on September 14

The presentation is scheduled for 2:00 p.m. EDT during the three-day event running September 14-16, 2026.

Morgan Stanley's 24th Annual Global Healthcare Conference hosts a fireside chat on September 16

The session is set for 1:05 p.m. EDT and will be streamed via a live audio webcast, with an archived replay available afterward on Protalix's investor relations site.